Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
1733
mi
from 98109
Chicago, IL
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
2006
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  12/31/1969
University Health Network-Princess Margaret Hospital
2066
mi
from 98109
Toronto,
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 12/31/1969
University Health Network-Princess Margaret Hospital
2066
mi
from 98109
Toronto,
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
1064
mi
from 98109
La Mesa, CA
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
1064
mi
from 98109
La Mesa, CA
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
984
mi
from 98109
Orange, CA
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
1020
mi
from 98109
Denver, CO
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Site
1723
mi
from 98109
Chicago, IL
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Site
1723
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
2328
mi
from 98109
Baltimore, MD
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Site
2485
mi
from 98109
Boston, MA
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Site
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
1933
mi
from 98109
Detroit, MI
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
1933
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
1450
mi
from 98109
Rochester, MN
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Site
2400
mi
from 98109
New York, NY
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Site
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Site
2400
mi
from 98109
New York, NY
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Site
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
2341
mi
from 98109
Durham, NC
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
146
mi
from 98109
Portland, OR
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
146
mi
from 98109
Portland, OR
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
6918
mi
from 98109
Buenos Aires,
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
6918
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated:  12/31/1969
Clinical Study Site
1721
mi
from 98109
Saint Louis, MO
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status: Enrolling
Updated: 12/31/1969
Clinical Study Site
1721
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Status: Enrolling
Updated:  12/31/1969
Clinical Site
2485
mi
from 98109
Boston, MA
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Status: Enrolling
Updated: 12/31/1969
Clinical Site
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
6898
mi
from 98109
Rio de Janeiro,
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
6898
mi
from 98109
Rio de Janeiro,
Click here to add this to my saved trials
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma
Status: Enrolling
Updated:  12/31/1969
University of Miami
2730
mi
from 98109
Miami, FL
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma
Status: Enrolling
Updated: 12/31/1969
University of Miami
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
2485
mi
from 98109
Boston, MA
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1040
mi
from 98109
Escondido, CA
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1040
mi
from 98109
Escondido, CA
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
705
mi
from 98109
Stanford, CA
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
705
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2449
mi
from 98109
Jacksonville, FL
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2449
mi
from 98109
Jacksonville, FL
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
7748
mi
from 98109
Darlinghurst,
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
7748
mi
from 98109
Darlinghurst,
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
1782
mi
from 98109
Little Rock, AR
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
1782
mi
from 98109
Little Rock, AR
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Mattel Children's Hospital
962
mi
from 98109
Los Angeles, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Mattel Children's Hospital
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
984
mi
from 98109
Orange, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Children's Hospital
707
mi
from 98109
Palo Alto, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Children's Hospital
707
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Lucile Packard Children's Hospital
707
mi
from 98109
Palo Alto, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Lucile Packard Children's Hospital
707
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
UC Davis Medical Center
627
mi
from 98109
Sacramento, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
UC Davis Medical Center
627
mi
from 98109
Sacramento, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
UCSF School of Medicine
682
mi
from 98109
San Francisco, CA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
UCSF School of Medicine
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta
2180
mi
from 98109
Atlanta, GA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta
2180
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
1733
mi
from 98109
Chicago, IL
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
James Whitcomb Riley Hospital for Children
1866
mi
from 98109
Indianapolis, IN
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
James Whitcomb Riley Hospital for Children
1866
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
2485
mi
from 98109
Boston, MA
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials